Breaking News

Cellular Biomedicine Expands into Arthritis Market

Gets IP go-ahead for Chinese market

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cellular Biomedicine Group, a biopharma firm engaged in the development of treatments for degenerative and cancerous diseases, plans to expand into the China Osteoarthritis and Rheumatoid Arthritis market. Following a complete analysis of current China patents by an intellectual property law firm, Cellular Biomedicine Group has clearance to pursue IP operation with respect to its patents for autologous and allogeneic adipose-derived stem cell compositions for the treatment of osteoarthritis and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters